
Osmol Therapeutics E.U. Patent Allowance for Novel Therapy Targeting Chemotherapy-induced Neuropathy
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced …